

119TH CONGRESS
2D SESSION

H. R. 1266

AN ACT

To prohibit certain uses of xylazine, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

1 **SECTION 1. SHORT TITLE.**

2 This Act may be cited as the “Combating Illicit
3 Xylazine Act”.

4 **SEC. 2. DEFINITIONS.**

5 (a) IN GENERAL.—In this Act, the term “xylazine”
6 has the meaning given the term in paragraph (61) of sec-
7 tion 102 of the Controlled Substances Act, as added by
8 subsection (b) of this section.

9 (b) CONTROLLED SUBSTANCES ACT.—Section 102 of
10 the Controlled Substances Act (21 U.S.C. 802) is amend-
11 ed by adding at the end the following:

12 “(61) The term ‘xylazine’ means the substance
13 xylazine, including its salts, isomers, and salts of isomers
14 whenever the existence of such salts, isomers, and salts
15 of isomers is possible.”.

16 **SEC. 3. ADDING XYLAZINE TO SCHEDULE III.**

17 Schedule III of section 202(c) of the Controlled Sub-
18 stances Act (21 U.S.C. 812) is amended by adding at the
19 end the following:

20 “(f) Unless specifically excepted or unless listed in
21 another schedule, any material, compound, mixture, or
22 preparation which contains any quantity of xylazine.”.

23 **SEC. 4. AMENDMENTS.**

24 (a) AMENDMENT.—Section 102 of the Controlled
25 Substances Act (21 U.S.C. 802) is amended by striking
26 paragraph (27) and inserting the following:

1 “(27)(A) Except as provided in subparagraph (B),
2 the term ‘ultimate user’ means a person who has lawfully
3 obtained, and who possesses, a controlled substance for
4 the use by the person or for the use of a member of the
5 household of the person or for an animal owned by the
6 person or by a member of the household of the person.

7 “(B)(i) In the case of xylazine, other than for a drug
8 product approved under subsection (b) or (j) of section
9 505 of the Federal Food, Drug, and Cosmetic Act (21
10 U.S.C. 355), the term ‘ultimate user’ means a person—

11 “(I) to whom xylazine was dispensed by—

12 “(aa) a veterinarian registered under this
13 Act; or

14 “(bb) a pharmacy registered under this
15 Act pursuant to a prescription of a veterinarian
16 registered under this Act; and

17 “(II) who possesses xylazine for—

18 “(aa) an animal owned by the person or by
19 a member of the household of the person;

20 “(bb) an animal under the care of the per-
21 son;

22 “(cc) use in government animal-control
23 programs authorized under applicable Federal,
24 State, Tribal, or local law; or

1 “(dd) use in wildlife programs authorized
2 under applicable Federal, State, Tribal, or local
3 law.

4 “(ii) In this subparagraph, the term ‘person’ in-
5 cludes—

6 “(I) a government agency or business where
7 animals are located; and

8 “(II) an employee or agent of an agency or
9 business acting within the scope of their employment
10 or agency.”.

11 (b) FACILITIES.—An entity that manufactures
12 xylazine, as of the date of enactment of this Act, shall
13 not be required to make capital expenditures necessary to
14 install the security standard required of schedule III of
15 the Controlled Substances Act (21 U.S.C. 801 et seq.) for
16 the purposes of manufacturing xylazine.

17 (c) LABELING.—The requirements related to label-
18 ing, packaging, and distribution logistics of a controlled
19 substance in schedule III of section 202(c) of the Con-
20 trolled Substances Act (21 U.S.C. 812(c)) shall not take
21 effect for xylazine until the date that is 1 year after the
22 date of enactment of this Act.

23 (d) PRACTITIONER REGISTRATION.—The require-
24 ments related to practitioner registration, inventory, and
25 recordkeeping of a controlled substance in schedule III of

1 section 202(c) of the Controlled Substances Act (21
2 U.S.C. 812(c)) shall not take effect for xylazine until the
3 date that is 60 days after the date of enactment of this
4 Act. A practitioner that has applied for registration during
5 the 60-day period beginning on the date of enactment of
6 this Act may continue their lawful activities until such ap-
7 plication is approved or denied.

8 (e) MANUFACTURER TRANSITION.—The Food and
9 Drug Administration and the Drug Enforcement Adminis-
10 tration shall facilitate and expedite the relevant manufac-
11 turer submissions or applications required by the place-
12 ment of xylazine on schedule III of section 202(c) of the
13 Controlled Substances Act (21 U.S.C. 812(c)).

14 (f) CLARIFICATION.—Nothing in this Act, or the
15 amendments made by this Act, shall be construed to re-
16 quire the registration of an ultimate user of xylazine under
17 the Controlled Substances Act (21 U.S.C. 801 et seq.) in
18 order to possess xylazine in accordance with subparagraph
19 (B) of section 102(27) of that Act (21 U.S.C. 802(27)),
20 as added by subsection (a) of this section.

21 **SEC. 5. ARCOS TRACKING.**

22 Section 307(i) of the Controlled Substances Act (21
23 U.S.C. 827(i)) is amended—

24 (1) in the matter preceding paragraph (1)—

1 (A) by inserting “or xylazine” after
2 “gamma hydroxybutyric acid”;

3 (B) by inserting “or 512” after “section
4 505”; and

5 (C) by inserting “respectively,” after “the
6 Federal Food, Drug, and Cosmetic Act,”; and

7 (2) in paragraph (6), by inserting “or xylazine”
8 after “gamma hydroxybutyric acid”.

9 **SEC. 6. SENTENCING COMMISSION.**

10 Pursuant to its authority under section 994(p) of title
11 28, United States Code, the United States Sentencing
12 Commission shall review and, if appropriate, amend its
13 sentencing guidelines, policy statements, and official com-
14 mentary applicable to persons convicted of an offense
15 under section 401 of the Controlled Substances Act (21
16 U.S.C. 841) or section 1010 of the Controlled Substances
17 Import and Export Act (21 U.S.C. 960) to provide appro-
18 priate penalties for offenses involving xylazine that are
19 consistent with the amendments made by this Act. In car-
20 rying out this section, the Commission should consider the
21 common forms of xylazine as well as its use alongside
22 other scheduled substances.

23 **SEC. 7. REPORT TO CONGRESS ON XYLAZINE.**

24 (a) INITIAL REPORT.—Not later than 18 months
25 after the date of the enactment of this Act, the Attorney

1 General, acting through the Administrator of the Drug
2 Enforcement Administration and in coordination with the
3 Commissioner of Food and Drugs, shall submit to Con-
4 gress a report on the prevalence of illicit use of xylazine
5 in the United States and the impacts of such use, includ-
6 ing—

- 7 (1) where the drug is being diverted;
- 8 (2) where the drug is originating; and
- 9 (3) whether any analogues to xylazine, or re-
10 lated or derivative substances, exist and present a
11 substantial risk of abuse.

12 (b) ADDITIONAL REPORT.—Not later than 4 years
13 after the date of the enactment of this Act, the Attorney
14 General, acting through the Administrator of the Drug
15 Enforcement Administration and in coordination with the
16 Commissioner of Food and Drugs, shall submit to Con-
17 gress a report updating Congress on the prevalence and
18 proliferation of xylazine trafficking and misuse in the
19 United States.

Passed the House of Representatives September 15,
2026.

Attest:

Clerk.

119TH CONGRESS
2^D SESSION

H. R. 1266

AN ACT

To prohibit certain uses of xylazine, and for other purposes.